Markets

The Zacks Analyst Blog Highlights: Juno, Amgen, Gilead, Intra-Cellular and TRACONThe Zacks Analyst Blog Highlights: Juno, Amgen, Gilead, Intra-Cellular and TRACON

For Immediate Release

Chicago, IL - September 24, 2015 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the like Juno ( JUNO ), Amgen ( AMGN ), Gilead ( GILD ), Intra-Cellular ( ITCI ) and TRACON ( TCON ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Wednesday's Analyst Blog:

Biotech Stock Roundup

Biotech stocks were hit hard by Democratic Presidential candidate Hillary Clinton's tweet about the pricing of drugs. Clinton's tweet about "price gouging" overshadowed all other developments in the biotech sector over the last five trading days.

Recap of the Week's Most Important Stories

1. Hillary Clinton's tweet on Monday regarding high drug prices spooked biotech investors and resulted in the NASDAQ Biotechnology index shedding 4.41% in just one trading session. Clinical-stage biotech stocks as well as companies with marketed products were affected by the presidential candidate's vow to fight drug pricing (Read more: 5 Biotech Stocks Hit Hard by Hillary Clinton's Tweet ). Companies like Juno ( JUNO ), which are still in the development stage, saw their share prices dipping reflecting concerns that their treatments, once approved, could be subjected to price control.

2. Amgen ( AMGN ) was in the news last week thanks to a couple of deals signed by the company with the intention of boosting its pipeline. Amgen said that it will be acquiring privately-held, Netherlands-based biotech company, Dezima, which is focused on developing treatments for dyslipidemia. Once the acquisition goes through, an oral, once-daily CETP inhibitor currently in mid-stage development will be added to Amgen's cardiovascular (CV) pipeline. Amgen has been building up its presence in the CV disease market and recently gained approval for two important products - Corlanor and Repatha (LDL-C lowering PCSK9 inhibitor).

The acquisition, slated to close later this year, could see Amgen shelling out up to $1.55 billion plus royalties. Meanwhile, Amgen also signed up with Xencor for the development of cancer immunotherapy and inflammation treatments (Read more: Amgen to Acquire Dezima Pharma, Strikes Deal with Xencor ).

3. Gilead ( GILD ) continues to show why it has such a strong presence in the hepatitis C virus (HCV) market. The company came out with positive late-stage data from four studies (ASTRAL-1, ASTRAL-2, ASTRAL-3 and ASTRAL-4) evaluating a once-daily, fixed-dose combination of Sovaldi (a nucleotide analog polymerase inhibitor) and velpatasvir (a pangenotypic NS5A inhibitor) for the treatment of genotype 1-6 chronic HCV infection. Approval would make this combination the first all-oral pan-genotypic single tablet regimen for chronic HCV. The company plans to file regulatory applications in the U.S. and EU in the fourth quarter (Read more: Gilead Unveils Encouraging HCV Data on Sovaldi/Velpatasvir ).

4. Intra-Cellular's ( ITCI ) shares shot up on positive top-line data on one of the doses (60 mg) of ITI-007 tested in a late-stage study for schizophrenia. ITI-007, the company's lead pipeline candidate, is currently in another phase III study (Read more: Intra-Cellular Up on Positive Data from Schizophrenia Study ).

5. TRACON ( TCON ) also saw its shares soaring on data from a single patient compassionate use mid-stage study on a 37-year old woman with persistent and unresectable metastatic choriocarcinoma, an aggressive form of gestational trophoblastic neoplasia (GTN). The company is now planning to start a phase II study in the fourth quarter in patients with GTN (Read more: TRACON Skyrockets on Positive Choriocarcinoma Study Data ).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Find out What is happening in the stock market today on zacks.com.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

JUNO THERAPEUTC (JUNO): Free Stock Analysis Report

AMGEN INC (AMGN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

INTRA-CELLULAR (ITCI): Free Stock Analysis Report

TRACON PHARMACT (TCON): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ITCI TCON GILD AMGN

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More